Orphenadrine is indicated as an adjunct to rest, physical therapy and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.
The company expects to roll out this product in the third quarter of 2011.
Sagent founder and chairman and CEO Yordon said this is another example of their commitment to the market by introducing a portfolio of quality injectable products.